Androgen blockade is the mainstay of therapy in the clinical management of advanced prostate cancer. Recent progress on two fronts--the development of newer xenograft and transgenic models and a greater understanding of nuclear receptor signaling--has provided new insight into mechanisms of androgen-dependence in prostate cancer. This review centers on the concept that perturbations in androgen receptor signaling are likely to occur early in prostate cancer and play a critical role in progression to end stage hormone-refractory disease.